Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 79,266,808
  • Shares Outstanding, K 109,326
  • Annual Sales, $ 12,173 M
  • Annual Income, $ 4,338 M
  • 60-Month Beta 0.23
  • Price/Sales 6.51
  • Price/Cash Flow 16.28
  • Price/Book 3.37
Trade REGN with:

Options Overview Details

View History
  • Implied Volatility 25.27% ( -0.47%)
  • Historical Volatility 23.28%
  • IV Percentile 9%
  • IV Rank 19.13%
  • IV High 41.71% on 09/29/22
  • IV Low 21.39% on 05/19/23
  • Put/Call Vol Ratio 0.51
  • Today's Volume 1,854
  • Volume Avg (30-Day) 2,626
  • Put/Call OI Ratio 0.91
  • Today's Open Interest 52,813
  • Open Int (30-Day) 54,727

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate 8.78
  • Number of Estimates 8
  • High Estimate 11.09
  • Low Estimate 6.82
  • Prior Year 9.77
  • Growth Rate Est. (year over year) -10.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
719.00 +0.84%
on 05/26/23
815.24 -11.06%
on 05/02/23
-52.95 (-6.81%)
since 04/26/23
3-Month
719.00 +0.84%
on 05/26/23
837.55 -13.43%
on 04/05/23
-31.94 (-4.22%)
since 02/24/23
52-Week
538.01 +34.77%
on 06/14/22
837.55 -13.43%
on 04/05/23
+41.61 (+6.09%)
since 05/26/22

Most Recent Stories

More News
4 Best Biotech Stocks According to POWR Ratings

Rapid advancements and soaring demand make the biotech sector well-positioned to witness significant growth in the foreseeable future. Given this backdrop, quality biotech stocks Amgen Inc. (AMGN), Regeneron...

AMGN : 216.93 (-0.24%)
REGN : 725.05 (+0.01%)
UTHR : 207.32 (-2.27%)
VNDA : 6.11 (+2.00%)
High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023

/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Kaitlyn Wang, 17, of San José, CA, won the $75,000 top...

REGN : 725.05 (+0.01%)
2 Cathie Wood Stocks That Can Get You Through Any Recession

Shares of both companies moved higher even as the stock market fell last year.

VRTX : 329.99 (-0.79%)
REGN : 725.05 (+0.01%)
Alnylam (ALNY) Q1 Earnings Beat, Product Sales Drive Revenues

Alnylam Pharmaceuticals (ALNY) reports better-than-expected first-quarter 2023 results. Givlaari, Oxlumo and the newly approved Amvuttra drive revenues for the company.

REGN : 725.05 (+0.01%)
ALNY : 188.26 (+1.22%)
NVS : 97.86 (+0.08%)
ADMA : 4.08 (+3.55%)
Intellia (NTLA) Beats on Q1 Earnings, Gives Pipeline Update

Intellia's (NTLA) first-quarter earnings beat estimates. The company provides updates on its gene-editing pipeline.

REGN : 725.05 (+0.01%)
NTLA : 38.98 (-0.61%)
ALLO : 5.53 (+1.10%)
OCUP : 3.89 (+7.16%)
Ultragenyx (RARE) Q1 Earnings and Revenues Miss Estimates

Ultragenyx Pharmaceutical's (RARE) first-quarter 2023 earnings and revenues miss estimates. The company maintains its 2023 guidance.

REGN : 725.05 (+0.01%)
RARE : 49.83 (-0.18%)
APTX : 0.0714 (-0.83%)
ETNB : 17.69 (+6.89%)
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales

Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo.

REGN : 725.05 (+0.01%)
RHHBY : 40.2600 (+0.90%)
SNY : 52.51 (-0.15%)
UNH : 481.52 (+0.80%)
JNJ : 154.35 (-0.04%)
XLV : 127.53 (-0.20%)
Stocks Tumble as Liquidity Concerns Rout Regional Bank Stocks

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Thursday closed down -0.72%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.86%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed...

$SPX : 4,205.45 (+1.30%)
SPY : 420.02 (+1.30%)
$DOWI : 33,093.34 (+1.00%)
DIA : 330.84 (+0.94%)
$IUXX : 14,298.41 (+2.58%)
QQQ : 348.40 (+2.56%)
PACW : 7.11 (+4.41%)
WAL : 35.52 (+0.25%)
FHN : 10.88 (-0.18%)
CMA : 38.99 (-0.51%)
ZION : 28.66 (+1.20%)
KEY : 9.89 (-2.18%)
Why Regeneron Pharmaceuticals Stock Is Tanking Today

Investors are worried about Eylea's falling sales.

AMD : 127.03 (+5.55%)
REGN : 725.05 (+0.01%)
Regeneron (REGN) Q1 Earnings & Sales Top, Eylea Sales Decline

Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea declined yet again.

REGN : 725.05 (+0.01%)
SNY : 52.51 (-0.15%)
RHHBY : 40.2600 (+0.90%)
BAYRY : 14.5900 (+1.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 735.99
2nd Resistance Point 731.38
1st Resistance Point 728.22
Last Price 725.05
1st Support Level 720.44
2nd Support Level 715.83
3rd Support Level 712.67

See More

52-Week High 837.55
Last Price 725.05
Fibonacci 61.8% 723.13
Fibonacci 50% 687.78
Fibonacci 38.2% 652.43
52-Week Low 538.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar